Authored By: Sarah
11 Jul 2024

 Infantile Spasms Therapeutics Market Size to grow by USD 89.61 million between 2024-2028

According to a research report “ Infantile Spasms Therapeutics Market” by Route Of Administration (Parenteral, Oral) Drug Class (Anticonvulsants, Corticosteroids, Others) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 89.61 million, at a CAGR of  5.41% during the forecast period. The global infantile spasms therapeutics market is experiencing significant growth due to ongoing neurology and epilepsy research, which is uncovering new treatment possibilities for this complex neurological condition. Discoveries in neurological networks and specific molecular markers are driving the development of more precise and effective medicines. Collaborative efforts between pharmaceutical companies and academic institutes are fostering a conducive environment for multidisciplinary investigation, leading to the identification of novel targets and breakthrough treatments. This research-driven approach is enhancing the overall efficacy and specificity of infantile spasms therapeutics, making a positive impact on patient outcomes.

Browse market data tables, figures, and in-depth TOC on “Infantile Spasms Therapeutics Market” by Route Of Administration (Parenteral, Oral) Drug Class (Anticonvulsants, Corticosteroids, Others) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample

 

By Route Of Administration, the Parenteral segment is projected to dominate the market size in 2024

In the global Infantile Spasms Therapeutics Market, anticonvulsants represent a significant drug class, playing a pivotal role in controlling and reducing seizures associated with this neurological condition. Drugs such as ACTH, vigabatrin, and oral corticosteroids, which belong to this class, have demonstrated success in mitigating spasms. Anticonvulsants' ability to modify neuronal activity and inhibit spasms makes them a heavily utilized therapeutic option. Ongoing research focuses on enhancing treatment efficacy, with a priority on developing novel anticonvulsants and combination therapies. Given anticonvulsants' indispensable role in Infantile Spasms Therapeutics, advancements and innovations within this drug class are anticipated to fuel the segment's growth throughout the forecast period, offering superior management solutions for those afflicted by this condition.

By Drug Class, Anticonvulsants  segment is expected to hold the largest market size for the year 2024

In the dynamic Infantile Spasms Therapeutics market, the parenteral route of administration is gaining significant traction due to its direct and efficient drug delivery capabilities. Parenteral formulations, such as intravenous and intramuscular injections, ensure rapid and precise medication distribution, which is vital in addressing the urgent treatment requirements of infantile spasms. Key therapeutics, including Adrenocorticotropic hormone (ACTH) and vigabatrin, are administered parenterally to enhance bioavailability and expedite therapeutic effects. This trend underscores the critical need for rapid intervention in infantile spasms treatment, positioning parenteral administration as a pivotal and increasingly preferred method for delivering therapeutics directly into the bloodstream for optimal efficacy.

North America is forecasted to hold the largest market size by region in 2024

The Infantile Spasms Therapeutics market in North America is experiencing robust growth, driven by a high prevalence rate, a well-developed healthcare infrastructure, and heightened awareness for early diagnosis and intervention. The region's thriving R&D ecosystem fosters innovation in therapeutic approaches, with leading pharmaceutical companies like Mallinckrodt and H. Lundbeck actively contributing through new drug development. Collaborative efforts among research institutions, healthcare providers, and advocacy groups further enhance the market landscape. Despite challenges, including the need for increased awareness and potential regulatory hurdles, the North American Infantile Spasms Therapeutics market is poised for continued expansion, providing advanced treatment options for individuals with this condition through a patient-centric approach, ongoing research initiatives, and a focus on precision medicine.

The Infantile Spasms Therapeutics Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • Amneal Pharmaceuticals Inc.
  • Cipla Ltd.
  • Endo International Plc
  • H Lundbeck AS
  • Hetero Labs Ltd.
  • Intas Pharmaceuticals Ltd.
  • Jazz Pharmaceuticals Plc
  • Mallinckrodt Plc
  • Marinus Pharmaceuticals Inc.
  • MSN Laboratories
  • Ovid Therapeutics Inc.
  • Sanofi SA
  • SGPharma Pvt. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Lifesciences Ltd.
  • Anavex Life Sciences Corp.
  • Genix Pharma Pvt. Ltd.
  • Jolly Healthcare
  • ORPHELIA Pharma
.

For insights on company offerings- Request a sample report!

Research Analysis Overview

Infantile spasms is a rare but serious epilepsy syndrome characterized by seizures, muscle stiffening, and jerky movements. Diagnosis typically involves a combination of neurological examination, physical examination, MRI, urine examinations, and blood tests. The therapeutic options for infantile spasms include monotherapy and combination therapy. Monotherapy involves the use of antiseizure medications, while combination therapy includes the use of glucocorticoids, corticotropin injection gel, and hormone therapy. Sustained results have been reported with steroids, which are the most commonly used treatment. Genetic changes, infection, birth injuries, and brain tumors can cause infantile spasms. Seizures can manifest as back arching, head bending forward, and stiffening of the legs, arms, and body during spasms. Infantile spasms usually occur in young children, typically between the ages of four months and one year. Treatment procedures aim to reduce the frequency and severity of seizures and improve developmental outcomes. The infantile spasms therapeutics market continues to evolve, with new therapeutic options under investigation.

Market Research Overview

The Infantile Spasms Therapeutics Market encompasses various drug types, including Adrenocorticotropic Hormone (ACTH) and Anticonvulsants, primarily Vigabatrin, which belong to the therapeutic class of Corticosteroids and Anticonvulsants, respectively. Segmentation of this market is based on disposable income levels, rapid urbanization, healthcare expenditure, and the undiagnosed patient pool. Key market players include private organizations, engaging in mergers and acquisitions and collaborations to expand their reach. The Infantile Spasms market is driven by innovative drugs, regulations, and awareness programs. The diagnostic process involves urine examinations, blood tests, MRI, neurological examination, and physical examination. Early diagnosis is crucial as Infantile Spasms, an epilepsy syndrome, affects young children, typically between the ages of four months and two years, and is characterized by seizures, including body stiffening, leg and arm jerking, and head bending forward. Therapeutic options include combination therapy, monotherapy, and hormone therapy, such as Glucocorticoids and Corticotropin injection gel. Success rates and penetration depend on factors like cost of treatment, seizure alert devices, and sustained results. Causes of Infantile Spasms include genetic changes, infections, birth injuries, and brain tumors. Successful treatment procedures can lead to significant improvements in the quality of life for affected children and their caregivers. The market is expected to grow due to increasing birth rates and newborn babies, with a significant potential for expansion in developing countries.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Read News Read Less
Interested in this report?
Get your sample now!
Technavio